Alkermes plc (ALKS) Quarterly EPS earnings growth

Alkermes Inc. - graphic logo of issuer ALKS

The stability of Alkermes plc (ALKS) is supported by strict control over the transportation of psychotropic substances, as confirmed by the recorded quarterly EPS dynamics. The current -81.90 indicator points to the yield status. Business efficiency is based on inelastic demand and long-acting injectables for the treatment of schizophrenia. Additional protection is provided by the Irish jurisdiction and the distribution of capacities between the US and the European Union, guaranteeing operational resilience.

Alkermes (ALKS) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 11/12/2026

ALKS (Alkermes Corp): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Quotes Alkermes|ALKS - Average Forecast Price
- market capitalization details:
Market Capitalization Alkermes Inc.|ALKS - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Alkermes|ALKS - Accounting Value of Company|Market Value to Book Value Ratio alkermes.com|ALKS - Company Assets
- debt and liquidity details:
Total Debt to Capital Alkermes plc|ALKS - Long-Term Debt to Capital|Short-Term Debt to Equity Alkermes plc|ALKS - Company Debts|Debt to Book Capitalization Ratio Alkermes Inc.|ALKS - Company Long-Term Debts|Company Short-Term Debts Alkermes|Quick Liquidity alkermes.com
- earnings and valuation multiples indicators:
ALKS - Final Profit|Expected Profit Alkermes plc|ALKS - Price to Earnings Ratio|Forward P/E Multiple Alkermes Inc.|ALKS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc.|ALKS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Alkermes|ALKS - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months alkermes.com|ALKS - Earnings per share trend in current year|Net earnings per share growth forecast for next year Alkermes plc
Fundamental valuation:Alkermes plc
Flagship merchandise of Alkermes plc

For the biopharmaceutical giant Alkermes plc (ALKS), earnings per share dynamics reflect the resilience of cash flows from licenses and drugs. The current quarterly EPS evolution captures a value of -81.90, calculated via a rolling comparison of net income. This method allows for the real-time assessment of fundamental business efficiency prior to the release of official reports. Inelastic demand for medications stabilizes this metric. It is critical for investors to correlate EPS growth with margins to avoid false signals.

Competitor analysis

AVDL (Avadel Pharmaceuticals plc) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months atai Life Sciences NV (ATAI)|GHRS (GH Research Corp) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Mind Medicine Corp (MNMD)|Quarterly EPS earnings growth CMPS|LBRX (lbpharma.us) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Bright Minds Biosciences Inc. DRUG|Vanda Pharma (VNDA) - Earnings per share growth in annualized terms for the last twelve months|Cybin Corp - Quarterly EPS earnings growth|ANRO - Quarterly EPS earnings growth|NRx Pharmaceuticals (NRXP) - Year-over-year earnings per share growth for the last twelve months|CING (Cingulate) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma|Quarterly EPS earnings growth China Pharma|Quarterly EPS earnings growth CMND|PBM - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Year-over-year earnings per one share growth for the last 12 months SEEL|VRPX - Year-over-year earnings per share growth for the last twelve months|Karuna Therapeutics Inc (KRTX) - Year-over-year net earnings per share growth for the last 12 months